Skip to main content
US EQUITIES OPEN CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
GK

GKOSStock

New York Stock Exchange · Healthcare · US

$238.12 as of 18 hours ago
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment GKOS's does — no target price to set, unlike a price alert.

Near limit Ratio screen, 7 of 7 decided standards passing. AAOIFI, Dow Jones Islamic, FTSE Shariah, MSCI Islamic, MSCI Islamic M-Series, S&P Shariah, Usmani are within 3 points of their line. If they all crossed, the majority verdict would move from Compliant to Not compliant. What would change it

Sharia status
COMPLIANT
Per our in-house ratio engine
7 of 7 pass our own screen — all 7 agree here
Purification 2.07% *HTR non-permissible income 2.11%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
🟡 BULLISH LEAN
The main driver: outperforming the market by 41.1%, RSI in healthy zone. More signals pointing up than down. Not...
Scores: 3 bullish / 0 bearish
43
of 100
Setup confidence — system conviction, not win probabilityD

Trade plan

Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.

MEAN_REVERSION
Entry
$233.08
Stop
$231.78
Target
$245.41
Risk : Reward 9.5R

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure3 of 5 timeframes bullish · 30.4% aligned
VWAPPrice below VWAP ($239.97)
VolumeRelative volume 1.5× the 20-day average
Momentum10-day rate of change +8.2%
Overall readBULLISH LEAN

GKOS is currently considered halal (Sharia-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Price target
$243.85
+2.4% · 13 analysts
Institutional own.
103.5% *
of shares
Momentum (10d)
+8.2%
rate of change
SMC grade
D · 43
30.4% aligned
2.07% *
Purification ratio (secondary provider, uncertain)
2.11%
Non-permissible income — HTR, from filings (2025-12-31)
D · 43
SMC grade — 30.4% timeframe alignment
+8.2%
Rate of change (10d)
$243.85
Price target (+2.4%) · 13 analysts
103.5%
Institutional ownership *

How the status reached this point

Compliant · status tracked since Nov 17, 2026

No change to GKOS’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from our own screen, last on Nov 19, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $14.5B as of 2026-11-17. At the 2026-11-19 close it is about $14.1B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing investments ratio would read 1.2% (1.1% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt (bound) at most 1.81% 30.00% Pass
Interest-bearing investments 1.14% 30.00% Pass(28.9pp buffer)
Non-permissible income 2.11% 5.00% Pass(2.9pp buffer)
Usmani Pass 5 of 5 ratios pass
RatioValueThresholdResult
Interest-bearing debt (bound) at most 26.77% 33.00% Pass
Interest-bearing investments 16.89% 33.00% Pass(16.1pp buffer)
Non-liquid assets 67.80% at least 20.00% Pass(47.8pp above the floor)
Non-permissible income 2.11% 5.00% Pass(2.9pp buffer)
Net liquid assets per share $188.7M under mkt cap $14.5B Pass
MSCI Pass 4 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt (bound) at most 26.77% 33.33% Pass
Cash + interest-bearing securities 16.89% 33.33% Pass(16.4pp buffer)
Accounts receivable 32.20% 33.33% Pass(1.1pp buffer)
Non-permissible income 2.11% 5.00% Pass(2.9pp buffer)
FTSE Pass 4 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt (bound) at most 26.77% 33.33% Pass
Cash + interest-bearing securities 16.89% 33.33% Pass(16.4pp buffer)
Accounts receivable 32.20% 50.00% Pass(17.8pp buffer)
Non-permissible income 2.11% 5.00% Pass(2.9pp buffer)
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt (bound) at most 3.54% 33.00% Pass
Cash + interest-bearing securities 2.23% 33.00% Pass(30.8pp buffer)
Accounts receivable 2.02% 33.00% Pass(31.0pp buffer)
Non-permissible income 2.11% 5.00% Pass(2.9pp buffer)
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt (bound) at most 3.88% 33.00% Pass
Cash + interest-bearing securities 2.45% 49.00% Pass(46.6pp buffer)
Accounts receivable 2.22% 49.00% Pass(46.8pp buffer)
Non-permissible income 2.11% 5.00% Pass(2.9pp buffer)
MSCI M-Series Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt (bound) at most 3.88% 33.33% Pass
Cash + interest-bearing securities 2.45% 33.33% Pass(30.9pp buffer)
Accounts receivable 4.67% 49.00% Pass(44.3pp buffer)
Non-permissible income 2.11% 5.00% Pass(2.9pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

MSCI Islamic Index (% of total assets)receivables ratio 1.1pts
AAOIFI Standard 21 (% of market cap)non permissible income ratio 2.9pts
Usmani (% of total assets)non permissible income ratio 2.9pts

The numbers the ratios are built from

Read from GKOS's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $507.4M 2025-12-31 RevenueFromContractWithCustomerExcludingAssessedTax
Interest-bearing debtBorrowings — which definition was stored is not recorded not measured — —
Cash and interest-bearing securitiesCash, equivalents and marketable securities $165.4M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $979.5M 2026-09-30 Assets
Market capDenominator for AAOIFI $14.5B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $6.6B 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $7.1B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $10.7M 2025-12-31 InterestAndOtherIncome

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-10-28, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-02-23, period ended 2025-12-31. Screened 2026-11-17.

  • Total assets$979.5M
    Assets · period ended 2026-09-30 · 10-Q filed 2026-10-28
  • Cash and interest-bearing securities$165.4M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · period ended 2026-09-30 · 10-Q filed 2026-10-28
  • Receivables$150.0M
    AccountsReceivableNetCurrent · period ended 2026-09-30 · 10-Q filed 2026-10-28
  • Revenue$507.4M
    RevenueFromContractWithCustomerExcludingAssessedTax · period ended 2025-12-31 · 10-K filed 2026-02-23
  • Interest income (non-permissible)$10.7M
    InterestAndOtherIncome · period ended 2025-12-31 · 10-K filed 2026-02-23
  • Market cap$14.5B
    Market quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-17 · not a filing figure, so no link

5 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.

What changed, and when

Verdict history for GKOS. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-11-17 Unverified → Pass filing re-screen

Tracked since 2026-09-07.

Revenue by business segment

How GKOS’s $507.4M of revenue for the fiscal year 2025-01-01 to 2025-12-31 splits across what it sells, as the company tags it in its own 10-K.

Fiscal year ended 2025-12-31
SegmentShareRevenue
Glaucoma 83.0% $421.1M
Corneal Health 17.0% $86.4M

These are the company’s own segment names and figures. They do not say whether a line of business is permissible; our business-activity screen does.

Source: 10-K filed 2026-02-23 (accession 0001193125-26-061944), read from its XBRL on SEC EDGAR. Shares are of total revenue; subtotals and overlapping cuts the filing also tags are left out, so the lines add up to the total.

What would change the status

The headline verdict is the majority of the decided ratio standards — 7 pass and 0 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-17.

Within 3 points of the line

AAOIFI, Dow Jones Islamic, FTSE Shariah, MSCI Islamic, MSCI Islamic M-Series, S&P Shariah, Usmani are within 3 points of their line. If they all crossed, the majority verdict would move from Compliant to Not compliant.

The ratios that move with the share price

AAOIFI's investments ratio (1.1% against a 30% line) would only fail if the market cap fell by 96%, to $551.5M. At the 2026-11-19 close it would read 1.2%.

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Medical Devices listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
ABTAbbott Laboratories $201.9B —
SYKStryker Corp. $125.7B —
MDTMedtronic Plc $117.8B —
BSXBoston Scientific Corp. $71.0B —
EWEdwards Lifesciences Corp $52.2B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold GKOS

13 of the 281 funds whose filed holdings we currently hold own GKOS shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns GKOS.

You may already own it

Widely held U.S. index funds. If you own one, you own GKOS through it. None of them is a Shariah fund; the last column is our look-through of each.

FundGKOS in fundFund compliant by weight
SCHB Schwab U.S. Broad Market ETF 0.01% 53%
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.01% 54%
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.01% 54%
Other funds
FundGKOS in fundFund compliant by weight
IJT iShares S&P Small-Cap 600 Growth ETF 0.62% 47%
SLYG State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF 0.62% 47%
FCDAX Fidelity Stock Selector Small Cap Fund 0.42% 40%
SLYV State Street(R) SPDR(R) S & P 600(TM) Small Cap Value ETF 0.28% 27%
ESML iShares ESG Aware MSCI USA Small-Cap ETF 0.22% 40%
IPSIX VOYA INDEX PLUS SMALLCAP PORTFOLIO 0.20% 38%
VPRSX VY(R) JPMORGAN SMALL CAP CORE EQUITY PORTFOLIO 0.14% 39%
CVMC Calvert US Mid-Cap Core Responsible Index ETF 0.08% 42%
GAB Gabelli Equity Trust Inc 0.02% 42%
GAB-PG Gabelli Equity Trust Inc 0.02% 42%

Sorted by GKOS’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names GKOS once, so a bond is not counted as the shares; 1 more fund name GKOS in a way we cannot separate from its bonds, and is not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding GKOS
InvestorFirmPositionWeightAs of
Israel Englander Millennium Management $266M 0.1% 2026-09-30
Ken Griffin Citadel Advisors $74M 0.0% 2026-09-30
Peter Brown Renaissance Technologies $44M 0.1% 2026-09-30
Steven Cohen Point72 Asset Management $33M 0.0% 2026-09-30
David Shaw D. E. Shaw & Co. $15M 0.0% 2026-09-30
Jefferies Jefferies Financial Group $9M 0.1% 2026-09-30
Polen Capital Polen Capital Management $5M 0.1% 2026-09-30
Ray Dalio Bridgewater Associates $4M 0.0% 2026-09-30
Mario Gabelli GAMCO Investors $1M 0.0% 2026-09-30
Joel Greenblatt Gotham Asset Management $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

247.16209.17171.18133.1995.202025-11-202026-05-262026-11-20

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
225.63
S2
228.62
S1
233.36
PIVOT
236.35
R1
241.09
R2
244.08
R3
248.82

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
135.72 – 173.82
±12.31% from 154.77, made 2026-09-25 · resolves 2026-10-02
STRONG SELL
from 19 indicators
78.6% of our last 30385 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG BUY
19 indicators
OscillatorsSTRONG BUY
2 buy · 4 neutral · 1 sell
Moving averagesSTRONG BUY
11 buy · 0 neutral · 1 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)62.60NEUTRAL
Stochastic %K (14)58.57NEUTRAL
CCI (20)37.27NEUTRAL
Williams %R (14)-41.43NEUTRAL
MACD (12,26,9)-1.62SELL
ROC (10)6.99BUY
Momentum (10)15.68BUY
EMA (10)237.56BUY
SMA (10)241.32SELL
EMA (20)227.03BUY
SMA (20)229.85BUY
EMA (30)217.06BUY
SMA (30)210.05BUY
EMA (50)203.27BUY
SMA (50)191.00BUY
EMA (100)183.19BUY
SMA (100)180.22BUY
EMA (200)156.36BUY
SMA (200)150.35BUY

About GKOS

Healthcare · Medical Devices

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

glaukos.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-11-19

MEAN REVERSION
Type
233.08
Entry
231.78
Stop
245.41
Target
LOSS
Outcome · exit 231.78 (-0.56%)

Stop 231.78 Now 238.12 Target 245.41

Verdict

🟡 BULLISH LEAN

The main driver: outperforming the market by 41.1%, RSI in healthy zone. More signals pointing up than down. Not full confluence yet, but the weight of evidence is bullish. Use `!alert GKOS [level]` to catch the entry, or `!plan GKOS` to size small.

Scores: 3 bullish / 0 bearish

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily RANGING 63
⏰ 4H RANGING 41
🕐 1H BULLISH 98
⏱ 15-Min BULLISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

+8.2%
Rate of change (10d)
1.5×
Volume vs its 20-day average
15.55
MACD (no fresh cross)
$237.94
Volume POC (today)
$235.05 – $238.91
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.